Has your child been diagnosed with a primary immunodeficiency disease (PIDD)?

Has your child been diagnosed with a primary immunodeficiency disease (PIDD)?

An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™

The Study

Primary Immunodeficiency is a condition that impairs the immune system and many people with PIDD receive immunoglobulin treatment as a replacement therapy.  The purpose of this study is to evaluate the safety and effectiveness of ASCENIV™, an FDA approved IVIG therapy when given to patients age 2-11 with Primary Immunodeficiency disease.

Study Benefits

  • Study participants may experience a reduction in severity and frequency of infections.
  • All study-related visits will be provided at no cost
  • Study participants will receive $150 for each completed study visit

Study Participant Criteria

  • Male or female patients between 2 and 11 years of age.
  • Must have a diagnosis of primary immunodeficiency disease.
  • Received IGIV therapy maintained at a steady dose for at least 3 months prior to screening

Study Participant Expectations

  • Participants will receive up to 7 infusions over a 5-7 month period of time
  • Blood and urine samples will be collected at periodic study visits
  • Total study participation will be 9 months

Register for a Study